CNIO researchers identify a new gene involved in the development of a rare endocrine tumour
(Centro Nacional de Investigaciones Oncol ó gicas (CNIO)) Paragangliomas and phaeochromocytomas are very rare neuroendocrine tumours and also the most hereditary form of all types of cancer. Researchers have for the first time linked mutations in the DLST gene with the development of such tumors. In addition to the importance of this finding for the future therapies, the discovery can broaden the number of families that may benefit from genetic counselling for prevention, detection and monitoring of these cancers. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 28, 2019 Category: Cancer & Oncology Source Type: news

Screening for Neuroendocrine Tumors Is Recommended for NF1 Patients
A study on pheochromocytoma and paraganglioma associated with neurofibromatosis type 1 highlights how screening for these malignancies is important. (Source: CancerNetwork)
Source: CancerNetwork - August 28, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Can Simple Clinical Factors Predict Metastatic Potential of Neuroendocrine Tumors?
Researchers have developed a clinical prediction model for the metastatic potential of pheochromocytoma and paraganglioma. (Source: CancerNetwork)
Source: CancerNetwork - August 24, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

FDA Approves Iobenguane I 131 for Rare Adrenal Gland Tumors
Intravenous Iobenguane I 131 has been approved to treat unresectable, locally advanced, or metastatic pheochromocytoma. (Source: CancerNetwork)
Source: CancerNetwork - August 7, 2018 Category: Cancer & Oncology Authors: John Schieszer Source Type: news

FDA approves Progenics' drug for rare tumors
The drug, Azedra, was approved to treat patients above the age of 12 who have either of the two tumors, pheochromocytoma or paraganglioma, and require anti-cancer therapy (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - July 31, 2018 Category: Pharmaceuticals Source Type: news

FDA Approves Azedra for Rare Adrenal Tumors
TUESDAY, July 31, 2018 -- Azedra (iobenguane) has been approved by the U.S. Food and Drug Administration to treat people 12 and older with rare adrenal gland tumors (pheochromocytoma or paraganglioma) that can ' t be surgically removed and have spread... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 31, 2018 Category: Pharmaceuticals Source Type: news

FDA approves first non-surgical treatment for 2 rare cancers
The Food and Drug Administration on Tuesday approved the first ever non-surgical treatment for the rare neuroendocrine cancers: pheochromocytoma and paraganglioma. The approval for Azedra, a drug developed by Progenics Pharmacecuticals of Tarrytown, N.Y., was based on a multi-center trial led by researchers in the Abramson Cancer Center of the University of Pennsylvania in Philadelphia. “This is a true breakthrough," said Dr. Daniel A. Pryma, an associate professor of radiology and radiation… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - July 31, 2018 Category: American Health Authors: John George Source Type: news

Therapy for Rare Cancers receives FDA approval following trials at Penn's Abramson Cancer
(University of Pennsylvania School of Medicine) The US Food and Drug Administration (FDA) has approved the first ever non-surgical treatment for the rare neuroendocrine cancers pheochromocytoma and paraganglioma. The approval was based on a multi-center trial led by researchers in the Abramson Cancer Center of the University of Pennsylvania and was granted to Progenics Pharmaceuticals for AZEDRA (iobenguane I131). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 31, 2018 Category: Cancer & Oncology Source Type: news